AR037936A1 - AMINOINDAN COMPOUNDS AS INHIBITORS OF THE ABSORPTION OF SEROTONINE AND NOREPINEFRINE, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOUNDS FOR THE PREPARATION OF MEDICINES - Google Patents
AMINOINDAN COMPOUNDS AS INHIBITORS OF THE ABSORPTION OF SEROTONINE AND NOREPINEFRINE, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOUNDS FOR THE PREPARATION OF MEDICINESInfo
- Publication number
- AR037936A1 AR037936A1 ARP020105023A ARP020105023A AR037936A1 AR 037936 A1 AR037936 A1 AR 037936A1 AR P020105023 A ARP020105023 A AR P020105023A AR P020105023 A ARP020105023 A AR P020105023A AR 037936 A1 AR037936 A1 AR 037936A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- cr6r7
- compounds
- alkyl
- hydrogen
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000003814 drug Substances 0.000 title abstract 3
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 title abstract 3
- 238000010521 absorption reaction Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- XJEVHMGJSYVQBQ-UHFFFAOYSA-N 2,3-dihydro-1h-inden-1-amine Chemical class C1=CC=C2C(N)CCC2=C1 XJEVHMGJSYVQBQ-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 150000002431 hydrogen Chemical class 0.000 abstract 3
- 208000019901 Anxiety disease Diseases 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 206010041250 Social phobia Diseases 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000019906 panic disease Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- 208000008811 Agoraphobia Diseases 0.000 abstract 1
- 206010010219 Compulsions Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 206010033664 Panic attack Diseases 0.000 abstract 1
- 206010034912 Phobia Diseases 0.000 abstract 1
- 230000009102 absorption Effects 0.000 abstract 1
- -1 aminoindane compound Chemical class 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 230000002301 combined effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229960002748 norepinephrine Drugs 0.000 abstract 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 230000009103 reabsorption Effects 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 201000001716 specific phobia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/58—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Un compuesto aminoindano de la fórmula (1), en la cual: X es -O-, -S- o -CR4R5-; Y es -CR6R7-, -CR6R7-CR8R9- o -CR6=CR7-; o X e Y juntos forman un grupo -CR4=CR5, o , -CR4=CR5-CR6R7; y U es -O-, -S- o CR10R11; o es -O-, -S- o -CR4R5-; e Y es U juntos forman un grupo CR6=CR7-, -CR6=CR7-CR10CR11-, ó, -CR6R7-CR10=CR11-; o, X, Y e U, juntos, forman -CR4=CR5-CR6=CR7-; R1 y R2 son independientemente el uno del otro seleccionados de entre el grupo consistente en hidrógeno, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-8, o, R1 y R2 juntos con el átomo de nitrógeno al cual están unidos, forman un anillo saturado de 3 a 7 miembros que opcionalmente contiene otro heteroátomo; R13, R14, R15 y R16, son, cada uno de ellos e independientemente el uno del otro, seleccionados de entre el grupo consistente en hidrógeno, halógeno, ciano, nitro, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, y cicloalquilo C3-6; R es hidrógeno, alquilo C1-6, o ciano; R4, R5, R6, R7, R8, R9, R10 y R11, son cada uno de ellos e independientemente el uno del otro, seleccionados de entre el grupo consistente en hidrógeno y alquilo C1-4; o una sal de adición de ácido, de los mismos. Estos compuestos poseen el efecto combinado, de la inhibición de la reabsorción de la serotonina y de la absorción de la norepinefrina. También se describen composiciones farmacéuticas y la utilización de un compuesto o de una sal del mismo, farmacéuticamente aceptable obtenida mediante la adición de un ácido, para la preparación de un medicamento para el tratamiento de los trastornos afectivos tales como la depresión y los trastornos de la ansiedad, que incluyen el trastorno general de la ansiedad, el trastorno de la ansiedad social, el trastorno del estrés post-traumático, el trastorno de la compulsión obsesiva, el trastorno del pánico, los ataques de pánico, las fobias específicas, la fobia social y la agorafobia.An aminoindane compound of the formula (1), in which: X is -O-, -S- or -CR4R5-; Y is -CR6R7-, -CR6R7-CR8R9- or -CR6 = CR7-; or X and Y together form a group -CR4 = CR5, or, -CR4 = CR5-CR6R7; and U is -O-, -S- or CR10R11; or is -O-, -S- or -CR4R5-; and Y is U together form a group CR6 = CR7-, -CR6 = CR7-CR10CR11-, or, -CR6R7-CR10 = CR11-; or, X, Y and U, together, form -CR4 = CR5-CR6 = CR7-; R1 and R2 are independently from each other selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C3-8 cycloalkyl, or, R1 and R2 together with the nitrogen atom at which are attached, form a saturated ring of 3 to 7 members that optionally contains another heteroatom; R13, R14, R15 and R16, are each and independently of each other, selected from the group consisting of hydrogen, halogen, cyano, nitro, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl , and C3-6 cycloalkyl; R is hydrogen, C1-6 alkyl, or cyano; R4, R5, R6, R7, R8, R9, R10 and R11 are each and independently of each other, selected from the group consisting of hydrogen and C1-4 alkyl; or an acid addition salt thereof. These compounds have the combined effect of inhibiting the reabsorption of serotonin and the absorption of norepinephrine. Pharmaceutical compositions and the use of a pharmaceutically acceptable compound or salt thereof obtained by the addition of an acid, for the preparation of a medicament for the treatment of affective disorders such as depression and disorders of the drug are also described. anxiety, which include general anxiety disorder, social anxiety disorder, post-traumatic stress disorder, obsessive compulsion disorder, panic disorder, panic attacks, specific phobias, social phobia and agoraphobia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200101939 | 2001-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR037936A1 true AR037936A1 (en) | 2004-12-22 |
Family
ID=33547528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020105023A AR037936A1 (en) | 2001-12-21 | 2002-12-19 | AMINOINDAN COMPOUNDS AS INHIBITORS OF THE ABSORPTION OF SEROTONINE AND NOREPINEFRINE, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH COMPOUNDS FOR THE PREPARATION OF MEDICINES |
Country Status (8)
| Country | Link |
|---|---|
| KR (1) | KR20040075904A (en) |
| AR (1) | AR037936A1 (en) |
| BR (1) | BR0214987A (en) |
| EA (1) | EA007655B1 (en) |
| IS (1) | IS7282A (en) |
| PL (1) | PL369525A1 (en) |
| UA (1) | UA76266C2 (en) |
| ZA (1) | ZA200403970B (en) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8628644D0 (en) * | 1986-12-01 | 1987-01-07 | Lunbeck A S H | Intermediates |
| DK286990D0 (en) * | 1990-12-04 | 1990-12-04 | Lundbeck & Co As H | indan derivatives |
| DK55192D0 (en) * | 1992-04-28 | 1992-04-28 | Lundbeck & Co As H | 1-piperazino-1,2-dihydroindene derivatives |
| GB9315566D0 (en) * | 1993-07-28 | 1993-09-08 | Smithkline Beecham Plc | Medicaments |
| GB9315600D0 (en) * | 1993-07-28 | 1993-09-08 | Smithkline Beecham Plc | Compounds |
| AU1867095A (en) * | 1994-01-10 | 1995-08-01 | Technion Research & Development Foundation Ltd. | 1-aminoindan derivatives and compositions thereof |
| WO1998055447A1 (en) * | 1997-06-05 | 1998-12-10 | Venantius Limited | 3-aminoindane derivatives, process for their preparation and pharmaceutical compositions containing them |
| CA2317591A1 (en) * | 1998-01-09 | 1999-07-15 | Pharm-Eco Laboratories Inc. | Synthesis of 3-aryl-1-indanamines |
-
2002
- 2002-05-21 IS IS7282A patent/IS7282A/en unknown
- 2002-12-18 UA UA20040705315A patent/UA76266C2/en unknown
- 2002-12-18 PL PL02369525A patent/PL369525A1/en not_active Application Discontinuation
- 2002-12-18 KR KR10-2004-7009905A patent/KR20040075904A/en not_active Withdrawn
- 2002-12-18 BR BR0214987-7A patent/BR0214987A/en not_active IP Right Cessation
- 2002-12-18 EA EA200400846A patent/EA007655B1/en not_active IP Right Cessation
- 2002-12-19 AR ARP020105023A patent/AR037936A1/en not_active Application Discontinuation
-
2004
- 2004-05-21 ZA ZA200403970A patent/ZA200403970B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA007655B1 (en) | 2006-12-29 |
| IS7282A (en) | 2004-05-21 |
| KR20040075904A (en) | 2004-08-30 |
| BR0214987A (en) | 2004-12-14 |
| UA76266C2 (en) | 2006-07-17 |
| ZA200403970B (en) | 2005-08-22 |
| EA200400846A1 (en) | 2004-12-30 |
| PL369525A1 (en) | 2005-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR036659A1 (en) | COMPOUNDS DERIVED FROM PHENYL-PIPERAZINE, PHENYL-PIPERIDINE AND PHENYL-TETRAHIDROPIRIDINE AS INHIBITORS OF THE REABSORTION OF SEROTONINE, A PHARMACEUTICAL COMPOSITION AND USE OF THE SAME FOR THE PREPARATION OF MEDICINES | |
| AR043700A1 (en) | DERIVATIVES OF 3-SUBSTITUIDA-4-PIRIMIDONA | |
| AR035479A1 (en) | DERIVATIVES OF BIARILIC ETERES AND THEIR SALTS, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND PROCEDURES FOR THE TREATMENT OF DISORDERS OR AFFECTIONS | |
| AR086357A1 (en) | INDAZOL DERIVATIVES ACTIVE SUBSTITUTES AS QUINASE INHIBITORS | |
| AR036598A1 (en) | DERIVATIVES OF 4,5-DIHIDRO-1H-PIRAZOL THAT HAVE POWERFUL CB1 ANTAGONIST ACTIVITY | |
| AR037429A1 (en) | DERIVATIVES OF PIPERIDINE ANTAGONISTS OF THE MCH, PHARMACEUTICAL COMPOSITIONS, A PROCESS FOR THEIR DEVELOPMENT AND THE USE OF SUCH DERIVATIVES, ONLY OR IN COMBINATION, FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF OBESITY AND DISORDERS OF THE SNC | |
| PE20240775A1 (en) | ANTIVIRAL COMPOUNDS | |
| AR083849A1 (en) | ESPIRO-OXINDOL MDM2 ANTAGONISTS | |
| JP2018065794A (en) | Fluorinated CBD compounds, compositions and uses thereof | |
| AR035733A1 (en) | THERAPEUTIC HETEROCICLIC COMPOUNDS, USE OF SUCH COMPOUNDS FOR THE PREPARATION OF MEDICINES, RELATED COMPOUNDS AND PROCEDURES TO PREPARE THESE RELATED COMPOUNDS | |
| AR077267A1 (en) | SELECTED INHIBITING NITROGEN DERIVATIVES OF PI3K, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME IN THE TREATMENT OF INFLAMMATORY AND / OR AUTOIMMUNE DISEASES. | |
| HRP20110400T1 (en) | 2-(1h-indolysulfanyl)-benzyl amine derivatives as ssri | |
| UY27503A1 (en) | NEW DERIVATIVES OF PIPERAZINA | |
| AR030244A1 (en) | HETEROCICLIC CARBOXAMIDS, PHARMACEUTICAL COMPOSITIONS, THE USE OF THE SAME FOR THE MANUFACTURE OF ANTIVIRAL MEDICINES AND AN IN VITRO METHOD TO INHIBIT THE VIRAL DNA POLYMERASE | |
| AR035815A1 (en) | PIPERIDINE DERIVATIVES, A PROCESS FOR THE PREPARATION, COMPOSITIONS AND PHARMACEUTICAL COMBINATIONS THAT INCLUDE SUCH DERIVATIVES | |
| AR031867A1 (en) | COMPOUNDS DERIVED FROM PHENOXIBENCILAMINE AS SSRI, ITS USE IN THE PREPARATION OF MEDICINES, PROCEDURE OF PREPARATION OF THE COMPOUND AND USEFUL INTERMEDIARIES | |
| AR058287A1 (en) | ISOQUINOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION | |
| PE20220937A1 (en) | MACROCYCLIC COMPOUNDS AS STING AGONISTS AND METHODS AND USES THEREOF | |
| AR029150A1 (en) | A PIPERIDINE DERIVATIVE, ITS EMPLOYMENT, A PROCEDURE TO PREPARE IT AND A PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT. | |
| EA201370184A1 (en) | Heteroaryl Derivatives | |
| AR035521A1 (en) | DERIVATIVES OF 3-INDOLIN AND PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS THEM | |
| AR040928A1 (en) | AROMATIC SULFONA-HYDROXAMIC ACID COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND ITS USE IN THE PREPARATION OF USEFUL DRUGS AS PROTEASE INHIBITORS | |
| ECSP088257A (en) | AMIDA DERIVATIVES | |
| AR065297A1 (en) | BIODISPONABLE FORMULATIONS OF HETEROCICLIC COMPOUNDS | |
| AR035083A1 (en) | AZAHETEROCICLILMETILIC DERIVATIVES OF 7,8-DIHIDRO-6H-5-OXA-1-AZA-FENANTRENE, PHARMACEUTICAL COMPOSITIONS, THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF AN ANTIDEPRESSIVE AND INTERMEDIARY MEDICINAL PRODUCT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |